Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study.

Amanzada A, Goralczyk AD, Schneider S, Moriconi F, Lindhorst A, Mihm S, Van Thiel DH, Ramadori G.

Digestion. 2012;86(3):218-27. doi: 10.1159/000339879. Epub 2012 Sep 5. Erratum in: Digestion. 2013;88(3):192.

PMID:
22964578
2.

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.

Amanzada A, Goralczyk A, Moriconi F, Blaschke M, Schaefer IM, van Thiel D, Mihm S, Ramadori G.

Dig Dis Sci. 2011 Nov;56(11):3296-304. doi: 10.1007/s10620-011-1933-2. Epub 2011 Oct 13.

3.

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.

Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.

PLoS One. 2011 Mar 30;6(3):e18322. doi: 10.1371/journal.pone.0018322.

4.

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T.

J Hepatol. 2011 Mar;54(3):415-21. doi: 10.1016/j.jhep.2010.07.041. Epub 2010 Sep 22.

PMID:
21112657
5.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
6.

Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.

Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, Mihm S, Ramadori G.

J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.

PMID:
22711348
7.

[IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].

Pár A, Pár G, Tornai I, Szalay F, Várszegi D, Fráter E, Papp M, Lengyel G, Fehér J, Varga M, Gervain J, Schuller J, Nemes Z, Péterfi Z, Tusnádi A, Hunyady B, Haragh A, Szinku Z, Pálinkás L, Berki T, Vincze A, Kisfali P, Melegh B.

Orv Hetil. 2013 Aug 11;154(32):1261-8. doi: 10.1556/OH.2013.29680. Hungarian.

PMID:
23916907
8.

Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.

Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS.

J Clin Gastroenterol. 2013 Aug;47(7):644-50. doi: 10.1097/MCG.0b013e3182896abf.

PMID:
23442843
9.

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

Petta S, Ferraro D, Cammà C, Cabibi D, Di Cristina A, Di Marco V, Di Stefano R, Grimaudo S, Mazzola A, Levrero M, Scazzone C, Craxì A.

Antivir Ther. 2012;17(5):823-31. doi: 10.3851/IMP2100. Epub 2012 Apr 13.

PMID:
22505587
10.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

PMID:
21068134
11.
12.

Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection.

Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R.

J Med Virol. 1999 Jul;58(3):227-34.

PMID:
10447417
13.

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.

J Gastroenterol. 2012 Oct;47(10):1143-51. doi: 10.1007/s00535-012-0578-z. Epub 2012 Mar 24.

PMID:
22441534
14.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

15.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

16.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
17.

Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandó OG, Silva MO.

Ann Hepatol. 2011 Oct-Dec;10(4):452-7.

18.

The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.

Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, Abdelmola A, Butt M.

Virology. 2013 Sep;444(1-2):292-300. doi: 10.1016/j.virol.2013.06.025. Epub 2013 Jul 16.

19.

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.

Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP.

J Hepatol. 2011 Aug;55(2):322-7. doi: 10.1016/j.jhep.2010.10.037. Epub 2010 Dec 13.

PMID:
21147186
20.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk